bioAffinity Technologies (NASDAQ:BIAF) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of bioAffinity Technologies (NASDAQ:BIAF) from a sell rating to a hold rating in a report published on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of bioAffinity Technologies in a research report on Monday, July 20th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has a consensus rating of “Sell”.

bioAffinity Technologies Stock Down 1.2%

Shares of bioAffinity Technologies stock opened at $0.66 on Friday. bioAffinity Technologies has a 1-year low of $0.61 and a 1-year high of $13.50. The company has a market capitalization of $3.13 million, a PE ratio of -0.06 and a beta of -1.11. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.36 and a quick ratio of 1.34. The business has a 50-day moving average of $1.14 and a 200-day moving average of $1.69.

bioAffinity Technologies (NASDAQ:BIAF) last issued its quarterly earnings results on Friday, May 8th. The company reported ($0.81) EPS for the quarter, beating analysts’ consensus estimates of ($2.40) by $1.59. bioAffinity Technologies had a negative return on equity of 285.75% and a negative net margin of 280.53%.The firm had revenue of $1.35 million during the quarter, compared to the consensus estimate of $1.48 million.

Institutional Investors Weigh In On bioAffinity Technologies

A number of institutional investors have recently modified their holdings of BIAF. Geode Capital Management LLC acquired a new position in bioAffinity Technologies in the fourth quarter worth about $36,000. Scientech Research LLC bought a new stake in bioAffinity Technologies in the third quarter valued at about $49,000. Finally, J. Safra Sarasin Holding AG bought a new stake in bioAffinity Technologies in the first quarter valued at about $164,000. Institutional investors and hedge funds own 1.64% of the company’s stock.

About bioAffinity Technologies

bioAffinity Technologies, Inc (NASDAQ: BIAF) is a U.S.-based biotechnology company specializing in the development and commercialization of advanced in vitro diagnostic platforms for oncology. Leveraging proprietary bioaffinity and nanotechnology approaches, bioAffinity’s platforms are designed to isolate and analyze cancer-specific biomarkers from blood, tissue, and other biological samples with high sensitivity and specificity. The company’s core technologies aim to enable earlier detection of solid tumors, improved disease monitoring, and more personalized treatment strategies.

The company’s primary product pipeline includes assays targeting breast cancer and other solid tumor indications.